Bio-Path Holdings Appoints New Auditor
Ticker: BPTH · Form: 8-K · Filed: Aug 13, 2025 · CIK: 1133818
| Field | Detail |
|---|---|
| Company | Bio-Path Holdings, Inc. (BPTH) |
| Form Type | 8-K |
| Filed Date | Aug 13, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: auditor-change, accounting
TL;DR
Bio-Path swapped auditors, bringing in BDO USA, LLP.
AI Summary
Bio-Path Holdings, Inc. filed an 8-K on August 13, 2025, to report changes in its certifying accountant. The company has appointed BDO USA, LLP as its new independent registered public accounting firm, effective August 13, 2025. This change follows the resignation of CohnReznick LLP.
Why It Matters
A change in auditors can signal potential issues with financial reporting or a strategic shift in how the company presents its financials to investors.
Risk Assessment
Risk Level: medium — Changes in auditors can sometimes precede or coincide with financial restatements or other disclosures that may impact stock price.
Key Players & Entities
- Bio-Path Holdings, Inc. (company) — Registrant
- BDO USA, LLP (company) — New Certifying Accountant
- CohnReznick LLP (company) — Former Certifying Accountant
- August 13, 2025 (date) — Effective date of appointment and resignation
FAQ
Who is Bio-Path Holdings, Inc.'s new independent registered public accounting firm?
Bio-Path Holdings, Inc. has appointed BDO USA, LLP as its new independent registered public accounting firm.
When was the change in auditor effective?
The change in auditor was effective as of August 13, 2025.
Who was Bio-Path Holdings, Inc.'s previous independent registered public accounting firm?
The previous independent registered public accounting firm for Bio-Path Holdings, Inc. was CohnReznick LLP.
What is the reason for the change in certifying accountant?
The filing indicates the resignation of CohnReznick LLP and the subsequent appointment of BDO USA, LLP.
What is the ticker symbol for Bio-Path Holdings, Inc.?
The filing does not explicitly state the ticker symbol, but the SEC file number is 001-36333.
Filing Stats: 791 words · 3 min read · ~3 pages · Grade level 12.7 · Accepted 2025-08-13 17:27:59
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share BPTH N/A Indicate by ch
Filing Documents
- tm2523449d1_8k.htm (8-K) — 30KB
- tm2523449d1_ex16-1.htm (EX-16.1) — 2KB
- 0001104659-25-077665.txt ( ) — 194KB
- bpth-20250813.xsd (EX-101.SCH) — 3KB
- bpth-20250813_lab.xml (EX-101.LAB) — 33KB
- bpth-20250813_pre.xml (EX-101.PRE) — 22KB
- tm2523449d1_8k_htm.xml (XML) — 4KB
01 Changes
Item 4.01 Changes in Registrant's Certifying Accountant. (a) Dismissal of Previous Independent Registered Public Accounting Firm . On August 13, 2025, the Board of Directors of Bio-Path Holdings, Inc. (the "Company") approved the dismissal of Ernst & Young LLP ("EY") as the Company's independent registered public accounting firm, and notified EY of the dismissal on the same date with an effective date of August 13, 2025. EY's reports on the Company's financial statements for the fiscal years ended December 31, 2024 and 2023 did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope, or accounting principles, except for the explanatory paragraph relating to the Company's ability to continue as a going concern contained in EY's reports on the Company's financial statements for each of the fiscal years ended December 31, 2024 and 2023. During the Company's two most recent fiscal years ended December 31, 2024 and 2023, and the subsequent interim period through August 13, 2025, there were (i) no "disagreements" within the meaning of Item 304(a)(1)(iv) of Regulation S-K and the related instructions thereto with EY on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of EY, would have caused it to make reference to the subject matter of the disagreements in connection with its reports on the financial statements of the Company for such years, and (ii) no "reportable events" within the meaning of Item 304(a)(1)(v) of Regulation S-K. The Company has provided EY with a copy of the foregoing disclosures and has requested that EY furnish the Company with a letter addressed to the SEC stating whether it agrees with such disclosures and, if not, stating the respects in which it does not agree. EY's letter is filed as Exhibit 16.1 to this Current Report on Form 8-K. The Company is activ
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 16.1* Letter of Ernst & Young LLP, dated August 13, 2025. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL (included as Exhibit 101).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-PATH HOLDINGS, INC. Dated: August 13, 2025 By: /s/ Doug P. Morris Doug P. Morris Chairman of the Board of Directors